Jun Hou
Fudan University
31 Papers
95 Citations
Jun Hou is an academic researcher from Fudan University. The author has contributed to research in topics: Cancer & Oxaliplatin. The author has an hindex of 8, co-authored 28 publications.
Chat about Author
Papers
A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis
Yan Wang,Yiyi Yu,Wei Li,Yi Feng,Jun Hou,Yuan Ji,Yihong Sun,Kun-tang Shen,Zhenbin Shen,Xinyu Qin,Tian-shu Liu +10 more
TL;DR: For gastric cancer patients with PAN involvement, neoadjuvant chemotherapy with XELOX demonstrated a good response rate, and a sufficient R0 resection rate, with acceptable toxicities.
Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models.
Xian-hua Wu,Jingchuan Zhang,Ruheng Zhen,Jing Lv,Li Zheng,Xinying Su,Guanshan Zhu,Paul R. Gavine,Song-Tao Xu,Shaohua Lu,Jun Hou,Yalan Liu,Chen Xu,Yunshan Tan,Liang Xie,Xiaolu Yin,Deming He,Qunsheng Ji,Yingyong Hou,Di Ge +19 more
TL;DR: This study demonstrates Trastuzumab-induced tumor regressions in HER-2 positive tumors, and highlights PIK3CA mutation as a potential resistance mechanism to Trastzumab treatment in pre-clinical patient-derived EC xenograft models.
Frequency, characterization, and prognostic analysis of PIK3CA gene mutations in Chinese esophageal squamous cell carcinoma
Jun Hou,Dongxian Jiang,Jingchuan Zhang,Paul R. Gavine,Songtao Xu,Yalan Liu,Chen Xu,Jie Huang,Yunshan Tan,Hao Wang,Yachao Lu,Li Zheng,Yingyong Hou,Lijie Tan +13 more
TL;DR: Interestingly, the frequency of PIK3CA mutation was higher in female ESCC patients than in males, and higher in patients with non-lymph node metastasis, suggesting that Pik3CA gene status may be a favorable predictive marker inESCC patients.
30
Platelet-to-lymphocyte ratio and lymphocyte-to-white blood cell ratio predict the efficacy of neoadjuvant chemotherapy and the prognosis of locally advanced gastric cancer patients treated with the oxaliplatin and capecitabine regimen.
TL;DR: In patients with LAGC treated with the oxaliplatin and capecitabine regimen as NAC, a low PLR (<130.7) and a high LWR (≥0.228) independently predicted a high ORR and pRR, while patients with high lymphocyte level tended to have a long OS and TTR.
Systematic analysis reveals molecular characteristics of ERG-negative prostate cancer.
Qingyu Xiao,Yidi Sun,Albert Dobi,Shiv Srivastava,Wendy Wang,Sudhir Srivastava,Yuan Ji,Jun Hou,Guo-Ping Zhao,Yixue Li,Hong Li +10 more
TL;DR: Both common and group-specific genomic alterations were observed, suggesting shared and different mechanisms of carcinogenesis in prostate cancer samples with or without ERG fusion, and may provide new opportunities for molecular stratification of ERG-negative prostate cancers.